Evidence map›Paper›PMID 38485690›Full record

ArticleBioinformatics (Oxford, England)2024

ArCH: improving the performance of clonal hematopoiesis variant calling and interpretation.

Irenaeus C C Chan, Alex Panchot, Evelyn Schmidt, Samantha McNulty, Brian J Wiley, Jie Liu, Kimberly Turner, Lea Moukarzel, Wendy S W Wong, Duc Tran and 16 more

Open access · goldAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 1 country.

Irenaeus C C ChanDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.ORCID 0009-0004-3250-9626
Alex PanchotDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Evelyn SchmidtDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Samantha McNultyInvitae Corporation, San Francisco, CA 94103, United States.
Brian J WileyDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Jie LiuDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.ORCID 0000-0001-6365-1888
Kimberly TurnerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Lea MoukarzelDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, United States.
Wendy S W WongDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20814, United States.
Duc TranDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
J Scott BeelerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Armel Landry Batchi-BouyouDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20814, United States.ORCID 0000-0001-6538-9705
Danielle M KaryadiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20814, United States.
Benjamin J KrajacichDepartment of Genomic Applications, Element BioSciences, San Diego, CA 92121, United States.
Junhua ZhaoDepartment of Genomic Applications, Element BioSciences, San Diego, CA 92121, United States.
Semyon KruglyakDepartment of Genomic Applications, Element BioSciences, San Diego, CA 92121, United States.
Bryan LajoieDepartment of Genomic Applications, Element BioSciences, San Diego, CA 92121, United States.
Shawn LevyDepartment of Genomic Applications, Element BioSciences, San Diego, CA 92121, United States.
Minal PatelDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, United States.
Philip W KantoffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, United States.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medical College, New York City, NY 10065, United States.
Daniel C LinkDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Todd E DruleyMission Bio, San Francisco, CA 94080, United States.
Konrad H StopsackDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.
Kelly L BoltonDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States.
Washington University in St. Louis · USMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USCornell University · USHarvard University · USInvitae (United States) · USMission Bio (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Specimen Acquistition and Expression ProfilingP01CA101937 · NCI · WASHINGTON UNIVERSITY · PI LINK, DANIEL C · 2003 to 2023
$58.8M
Impact of Oncologic Therapy on Clonal Hematopoiesis and Subsequent Risk of Therapy-Related LeukemiaK08CA241318 · NCI · WASHINGTON UNIVERSITY · PI BOLTON, KELLY LEIGH · 2019 to 2023
$1.2M
American Society of HematologyEdward P. Evans FoundationNCI NIH HHS K08 CA241318NCI NIH HHS P01 CA101937NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

motivationThe acquisition of somatic mutations in hematopoietic stem and progenitor stem cells with resultant clonal expansion, termed clonal hematopoiesis (CH), is associated with increased risk of hematologic malignancies and other adverse outcomes. CH is generally present at low allelic fractions, but clonal expansion and acquisition of additional mutations leads to hematologic cancers in a small proportion of individuals. With high depth and high sensitivity sequencing, CH can be detected in most adults and its clonal trajectory mapped over time. However, accurate CH variant calling is challenging due to the difficulty in distinguishing low frequency CH mutations from sequencing artifacts. The lack of well-validated bioinformatic pipelines for CH calling may contribute to lack of reproducibility in studies of CH.

resultsHere, we developed ArCH, an Artifact filtering Clonal Hematopoiesis variant calling pipeline for detecting single nucleotide variants and short insertions/deletions by combining the output of four variant calling tools and filtering based on variant characteristics and sequencing error rate estimation. ArCH is an end-to-end cloud-based pipeline optimized to accept a variety of inputs with customizable parameters adaptable to multiple sequencing technologies, research questions, and datasets. Using deep targeted sequencing data generated from six acute myeloid leukemia patient tumor: normal dilutions, 31 blood samples with orthogonal validation, and 26 blood samples with technical replicates, we show that ArCH improves the sensitivity and positive predictive value of CH variant detection at low allele frequencies compared to standard application of commonly used variant calling approaches. AVAILABILITY AND IMPLEMENTATION: The code for this workflow is available at: https://github.com/kbolton-lab/ArCH.

Indexed as

Clonal HematopoiesisHematologic NeoplasmsAdultHematopoiesisHigh-Throughput Nucleotide SequencingHumansMutationReproducibility of ResultsSoftware

Identifiers

PMID38485690
PMCPMC11014783
OpenAlexW4392886184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.